Research Topics
Species | J A GlaspySummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfaJohn Glaspy
UCLA, School of Medicine, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6956, USA
Eur J Cancer 41:1140-9. 2005....- The potential for anemia treatment to improve survival in cancer patientsJohn A Glaspy
Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
Oncology (Williston Park) 16:35-40. 2002..This article reviews the data available regarding the impact of anemia on the survival of cancer patients... - Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanomaLynn K Gordon
Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA
Control Clin Trials 25:400-7. 2004..Therefore, surveillance of the eye and vision should be considered in melanoma immunotherapy trials... - Cancer patient survival and erythropoietinJohn A Glaspy
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA 90095 6956, USA
J Natl Compr Canc Netw 3:796-804. 2005..For the present, it is prudent to withhold ESP therapy unless hemoglobin concentrations fall below 12 g/dL and to titrate treatment to maintain a target of 12 g/dL, with adjustments in therapy to insure that levels do not exceed 13 g/dL... - Erythropoiesis-stimulating agents in oncologyJohn A Glaspy
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
J Natl Compr Canc Netw 6:565-75. 2008..This article reviews relevant preclinical and clinical available data to help improve understanding and guide decision making... - Update on safety of ESAs in cancer-induced anemiaJohn Glaspy
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6956, USA
J Natl Compr Canc Netw 10:659-66. 2012..Until additional safety data are forthcoming, ESAs should be used only to treat chemotherapy-induced anemia, with the goal of preventing transfusions. Patients and physicians should be aware of the safety data for these products... - Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutationsFranziska Niehr
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
J Transl Med 9:76. 2011..A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines... - Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaAntoni Ribas
University of California Los Angeles UCLA, CA, USA
J Transl Med 8:89. 2010.... - Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaBegona Comin-Anduix
Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
J Transl Med 6:22. 2008..CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated... - Use of complementary/alternative therapies by women with advanced-stage breast cancerJoannie Shen
Laboratory of Clinical Sciences, National Institute of Alcoholism and Alcohol Abuse, National Institutes of Health, Bethesda, MD, USA
BMC Complement Altern Med 2:8. 2002.... - Can erythropoietin therapy improve survival?John Glaspy
University of California, Los Angeles School of Medicine, 90095, USA
Oncology 67:5-11. 2004..These results suggest that treatment of anaemic patients with cancer with epoetin beta is effective and safe... - Entering a new era in the management of tumor-associated involutionJohn A Glaspy
Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California 90095, USA
J Support Oncol 3:51-2. 2005 - Hematopoietic management in oncology practice. Part 2. Erythropoietic factorsJohn A Glaspy
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA
Oncology (Williston Park) 17:1724-30; discussion 1731-2, 1735, 1739. 2003..Thrombopoietic factors and progenitor cell-mobilizing factors are also briefly addressed... - Hematopoietic management in oncology practice. Part 1. Myeloid growth factorsJohn A Glaspy
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA
Oncology (Williston Park) 17:1593-603. 2003..In randomized trials, rhG-CSF has consistently decreased the duration of neutropenia during all cycles of chemotherapy and reduced the risk of infection by 50% or more. Trials of rhGM-CSF have not reported consistent results... - The development of erythropoietic agents in oncologyJohn A Glaspy
Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095 6956, USA
Expert Opin Emerg Drugs 10:553-67. 2005..A large body of data suggests that these agents are safe when used in accordance with the package inserts. The data bearing upon these issues will be reviewed and three new agents entering clinical development will be described... - Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon)John Glaspy
University of California, Los Angeles School of Medicine, Los Angeles, CA 90095, USA
Oncology 69:8-16. 2005..Ongoing studies are expected to lead to a greater understanding of the optimal use of epoetins in cancer-related anaemia... - Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group TrialJohn Glaspy
University of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA
J Clin Oncol 24:2290-7. 2006..This noninferiority study systematically compares efficacy and safety of DA and EA using common doses and schedules used in clinical practice... - Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemiaJohn Glaspy
Clinical Research Unit, UCLA School of Medicine, Los Angeles, California 90095 7077, USA
Oncology (Williston Park) 20:29-32. 2006..Synchronous administration of darbepoetin alfa with chemotherapy is a convenient option for patients with chemotherapy-induced anemia, with clinical trials showing it to be an effective treatment strategy... - Erythropoietin in cancer patientsJohn A Glaspy
Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, California 90095, USA
Annu Rev Med 60:181-92. 2009..Although the preponderance of the data suggests that ESAs do not alter survival when used to treat chemotherapy-induced anemia, large well-controlled trials addressing this issue are needed... - Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment armsJohn A Glaspy
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
Cancer 115:1121-31. 2009..This study evaluated a starting dose of epoetin-alpha 120,000 U once every 3 weeks for chemotherapy-induced anemia using early and late initiation regimens... - Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomesJ Glaspy
Department of Medicine Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095 6996 USA
Br J Cancer 102:301-15. 2010..To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events... - A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant diseaseJohn A Glaspy
Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095 6956, USA
Cancer 97:1312-20. 2003..Darbepoetin alpha, a new erythropoietic agent, has longer serum residence time, allowing it to be administered less frequently... - Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapyJohn A Glaspy
UCLA School of Medicine, UCLA Oncology Center, Los Angeles, California, USA
Oncology (Williston Park) 16:23-9. 2002..A dose increase to 5.0 microg/kg of darbepoetin alfa administered every 2 weeks may be appropriate in patients with an inadequate initial response... - Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanomaJohn Glaspy
Department of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
Cancer 115:5228-36. 2009.... - Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapyJ A Glaspy
Br J Cancer 87:268-76. 2002..Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy... - Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiencyJohn A Glaspy
Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
Oncology (Williston Park) 16:71-7. 2002..The characteristics of darbepoetin alfa suggest the ability to improve overall quality of erythropoietic therapy, which may increase its utilization in patients who would benefit from such treatment... - Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanomaLisa H Butterfield
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 31:294-309. 2008..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma... - Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206Antoni Ribas
Department of Medicine, Division of Hematology/Oncology Surgery, University of California at Los Angeles, CA, USA
J Clin Oncol 23:8968-77. 2005..CONCLUSION: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma... - Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)Lana Y Schumacher
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles 90095, USA
J Immunol 176:4757-65. 2006..In conclusion, the proteasome inhibitor bortezomib can pharmacologically sensitize tumor cells to the lytic effects of DC-activated immune effector cells... - Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapyAntoni Ribas
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
J Immunother (1997) 27:354-67. 2004..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy... - Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanomaLisa H Butterfield
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA
Clin Cancer Res 9:998-1008. 2003.... - Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cellsJennifer A Wargo
Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
Cancer Gene Ther 12:516-27. 2005..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells... - Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivoR L Paquette
UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA 90095-1678, USA
Leukemia 16:1484-9. 2002..The therapeutic activity of IFN-alpha in CML may be due to its ability to stimulate the generation of DCs that can present CML-specific antigens. Resistance to IFN-alpha may result when DC differentiation becomes impaired... - T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancerLisa H Butterfield
Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
Clin Cancer Res 9:5902-8. 2003..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides... - Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram
Department of Medical Oncology, The University of California at Los Angeles, USA
J Clin Oncol 16:2659-71. 1998..v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer... - Cancer immunotherapy using gene-modified dendritic cellsAntoni Ribas
Departments of Surgery, Medicine, Division of Hematology Oncology, 11 934 Factor Bldg UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
Curr Gene Ther 2:57-78. 2002..These data may help in the translation of this promising approach to the clinic... - Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanomaBradley R Straatsma
Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California 90095, USA
Am J Ophthalmol 143:958-969. 2007..To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma... - Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
Neoplasia 12:637-49. 2010..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma... - Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockadeAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:390-9. 2009..In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity... - Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanomaAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:6267-76. 2009..The combination was tested in a phase I clinical trial in patients with advanced melanoma... - Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recoveryRonald L Paquette
Department of Medicine, Division of Hematology Oncology, 42 121 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Exp Hematol 30:374-80. 2002..The aim of this study was to evaluate the effect of various ex vivo expansion conditions on the cell products and their ability to accelerate hematopoietic recovery in patients undergoing stem cell transplantation... - Do we need a different set of response assessment criteria for tumor immunotherapy?Antoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:7116-8. 2009..In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria... - Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assaysBegona Comin-Anduix
Department of Surgery, Division of Surgical, University of California at Los Angeles, Los Angeles, California, USA
Clin Cancer Res 12:107-16. 2006..Define an immunologic response using the tetramer and enzyme-linked immunospot (ELISPOT) assays... - Current developments in cancer vaccines and cellular immunotherapyAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, 90095 1782, USA
J Clin Oncol 21:2415-32. 2003.... - Broad antitumor protection by dendritic cells administered to CD8alpha knock out miceAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, 90095, USA
Cancer Immunol Immunother 55:663-71. 2006..3) In sensitive targets a putative activating NK ligand in DC-stimulated NK cells from CD8alphaKO mice signals directly to PI3-K, but is distinct from NKG2D... - Enhanced tumor responses to dendritic cells in the absence of CD8-positive cellsAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
J Immunol 172:4762-9. 2004..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches... - Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cellsR L Paquette
Department of Medicine, The University of California at Los Angeles, 90095 1678, USA
J Leukoc Biol 64:358-67. 1998..These results demonstrate an important role for IFN-alpha in the generation of DCs with potent antigen-presenting capabilities from peripheral blood monocytes... - Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancerR L Paquette
Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA
Blood 96:2385-90. 2000..Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy... - alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccinationW S Meng
Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California 90095, USA
Cancer Res 61:8782-6. 2001..This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma... - A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptidesLisa H Butterfield
Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 12:2817-25. 2006..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen... - T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoproteinL H Butterfield
Division of Surgical Oncology, Department of Chemistry and Biochemistry, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA
J Immunol 166:5300-8. 2001.... - Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancerW J Aronson
Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90095-1738, USA
Urology 58:283-8. 2001..The potential for this diet to prevent the development and progression of prostate cancer by way of altered COX-2 expression and prostaglandin production in prostatic tissue requires further study... - CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cellsA Ribas
Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California 90095, USA
Cancer Res 61:8787-93. 2001..In conclusion, maturation of AdVMART1-transduced DCs through the CD40 ligation pathway can promote a protective CD8 T-cell-mediated immunity that is independent of CD4 T-cell help... - Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2Naoko Kobayashi
Department of Urology, Division of Clinical Nutrition and Hematology-Oncology, University of California, Los Angeles School of Medicine, 90095-1738, USA
Clin Cancer Res 12:4662-70. 2006.... - Therapeutic options in the management of renal cell carcinomaJohn A Glaspy
Bowyer Oncology Center, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
Semin Oncol 29:41-6. 2002..Expansion of activated T cells in blood during treatment with these two cytokines seems to relate to clinical efficacy in patients with RCC... - Novel interactions of vitamin E and estrogen in breast cancerHilda Chamras
Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine 90095 1678, USA
Nutr Cancer 52:43-8. 2005..This provides evidence that vitamin E may inhibit ER-positive cell growth by altering the cellular response to estrogen... - Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancerDilprit Bagga
Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095, USA
Nutr Cancer 42:180-5. 2002..09). We conclude that total n-6 PUFAs may be contributing to the high risk of breast cancer in the United States and that LC n-3 PUFAs, derived from fish oils, may have a protective effect... - Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapyJeffrey Crawford
Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
Cancer 95:888-95. 2002..These data suggest that the maximal incremental gain in QOL occurs when hemoglobin is in the range of 11-13 g/dL... - Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled studyRobert E Smith
South Carolina Oncology Associates, Columbia, SC, USA
J Clin Oncol 26:1040-50. 2008..The efficacy and safety of darbepoetin alpha (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated... - Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccinesAntoni Ribas
Department of Surgery, University of California at Los Angeles, 90095-1782, USA
Cancer Gene Ther 9:875-83. 2002..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection... - Standards of care for anemia management in oncology: focus on lung carcinomaCorey J Langer
Department of Thoracic Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Cancer 95:613-23. 2002..Evidence is growing that anemia can have a profound impact on the patient's quality of life, often manifested as the patient's inability to function normally... - High-molecular weight iron dextran: a wolf in sheep's clothing?George M Rodgers
J Am Soc Nephrol 19:833-4. 2008